TMPRSS2 and prostate cancer: Gene fusions involving the androgen-regulated gene TMPRSS2 and ERG occur in about 50% of prostate cancers and result in strong ERG protein overexpression [30] with consequent deregulation of the expression of a large number of genes [31–34].